All‐cause and cardiovascular mortality risk after surgery versus radioiodine treatment for hyperthyroidism. BJS 2018; 105: 279-286.
Published: 8th November 2017
Authors: P. Giesecke, V. Frykman, G. Wallin, S. Lönn, A. Discacciati, O. Törring et al.
Little is known about the long‐term side‐effects of different treatments for hyperthyroidism. The few studies previously published on the subject either included only women or focused mainly on cancer outcomes. This register study compared the impact of surgery
Healthcare registers were used to find hyperthyroid patients over 35 years of age who were treated with radioiodine or surgery between 1976 and 2000. Comparisons between treatments were made to assess all‐cause and cause‐specific deaths to 2013. Three different statistical methods were applied: Cox regression, propensity score matching and inverse probability weighting.
Of the 10 992 patients included, 10 250 had been treated with radioiodine (mean age 65·1 years; 8668 women, 84·6 per cent) and 742 had been treated surgically (mean age 44·1 years; 633 women, 85·3 per cent). Mean duration of follow‐up varied between 16·3 and 22·3 years, depending on the statistical method used. All‐cause mortality was significantly lower among surgically treated patients, with a hazard ratio of 0·82 in the regression analysis, 0·80 in propensity score matching and 0·85 in inverse probability weighting. This was due mainly to lower cardiovascular mortality in the surgical group. Men in particular seemed to benefit from surgery compared with radioiodine treatment.
Compared with treatment with radioiodine, surgery for hyperthyroidism is associated with a lower risk of all‐cause and cardiovascular mortality in the long term. This finding was more evident among men.Full text
You may also be interested in
Meta‐analysis of in‐hospital delay before surgery as a risk factor for complications in patients with acute appendicitis. BJS 2018; 105: 933-945.
Authors: S. T. van Dijk, A. H. van Dijk, M. G. Dijkgraaf, M. A. Boermeester
Notes: Delay is safe
Authors: T. G. Weiser, A. B. Haynes
Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. BJS 2018; 105: 946-958.
Authors: E. Versteijne, J. A. Vogel, M. G. Besselink, O. R. C. Busch, J. W. Wilmink, J. G. Daams et al.
Notes: Improved survival with neoadjuvant treatment
Meta‐analysis evaluating music interventions for anxiety and pain in surgery. BJS 2018; 105: 773-783.
Authors: A. Y. R. Kühlmann, A. de Rooij, L. F. Kroese, M. van Dijk, M. G. M. Hunink, J. Jeekel et al.
Prognostic significance of gross extrathyroidal extension invading only strap muscles in differentiated thyroid carcinoma.
Authors: S. Y. Park, H. I. Kim, J.‐H. Kim, J. S. Kim, Y. L. Oh, S. W. Kim et al.
Notes: None for survival
Authors: M. Almquist, K. Ivarsson, E. Nordenström, A. Bergenfelz
Notes: Higher than expected
Authors: F. P. Prete, T. Abdel‐Aziz, C. Morkane, C. Brain, T. R. Kurzawinski, P. Hindmarsh et al.
Notes: Centralization needed
Authors: M. Mansourati, V. Kumar, M. Khajanchi, M. L. Saha, S. Dharap, R. Seger et al.
Notes: High burden of late mortality
Interobserver variability in the classification of appendicitis during laparoscopy. BJS 2018; 105: 1014-1019.
Authors: A. L. van den Boom, E. M. L. de Wijkerslooth, K. A. L. Mauff, I. Dawson, C. C. van Rossem, B. R. Toorenvliet et al.
Development and evaluation of a patient‐centred measurement tool for surgeons’ non‐technical skills. BJS 2018; 105: 876-884.
Authors: J. Yule, K. Hill, S. Yule
Notes: Valid and reliable